Literature DB >> 28321926

Evaluation of 30 cases of mucormycosis at a university hospital in Iran.

Reza Samarei1, Naser Gharebaghi2, Salar Zayer3.   

Abstract

Mucormycosis is a deadly invasive fungal infection and mainly affects immunocompromised patients. To investigate the clinical features of patients who developed mucormycosis and to determine the parameters, which influenced the outcome following mycotic infection. The current investigation retrospectively evaluated the demographic characteristics, clinical features, therapeutic data, as well as the outcomes of treatment in all cases of proven and probable mucormycosis diagnosed from 2002 until 2016 in our hospital. A total of thirty cases were recorded. Rhizopus spp. was the predominant pathogen among the identified Mucorales (26.7%). Diabetes mellitus (46.7%) and haematological malignancy (40%), were the most common underlying diseases. With regard to predisposing factors, neutropenia (43.3%) and chemotherapy (40%) were the leading concomitant parameters. The most frequent sites of infection were lung (30%) and sinus (26.7%), whereas disseminated infection was also found in nine of 30 patients (30%). Neutropenia remained the only independent factor associated with mortality (Relative Risk=3.557, 95% CI=1.365-9.271, P=.009). Diagnostic delay -either due to delayed presentation of patients to our centre or insufficient awareness about invasive fungal infection among our clinicians- is a likely explanation for such a high mortality rate in our series.
© 2017 Blackwell Verlag GmbH.

Entities:  

Keywords:  epidemiology; mortality; mucormycosis; university hospital

Mesh:

Year:  2017        PMID: 28321926     DOI: 10.1111/myc.12614

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  5 in total

1.  Antifungal Susceptibility Testing of Malassezia spp. with an Optimized Colorimetric Broth Microdilution Method.

Authors:  Cheryl Leong; Antonino Buttafuoco; Martin Glatz; Philipp P Bosshard
Journal:  J Clin Microbiol       Date:  2017-04-05       Impact factor: 5.948

2.  Pulmonary Mucormycosis in Chronic Lymphocytic Leukemia and Neutropenia.

Authors:  Izza Mir; Sijan Basnet; David Ellsworth; Elan Mohanty
Journal:  Case Rep Infect Dis       Date:  2018-02-19

Review 3.  A Guide to Investigating Suspected Outbreaks of Mucormycosis in Healthcare.

Authors:  Kathleen P Hartnett; Brendan R Jackson; Kiran M Perkins; Janet Glowicz; Janna L Kerins; Stephanie R Black; Shawn R Lockhart; Bryan E Christensen; Karlyn D Beer
Journal:  J Fungi (Basel)       Date:  2019-07-24

4.  Epidemiology, clinical features, therapeutic interventions and outcomes of mucormycosis in Shiraz: an 8-year retrospective case study with comparison between children and adults.

Authors:  Marjan Motamedi; Zahra Golmohammadi; Somayeh Yazdanpanah; S Mojtaba Saneian; Mojtaba Shafiekhani
Journal:  Sci Rep       Date:  2022-10-13       Impact factor: 4.996

5.  Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: An observational study.

Authors:  Manouchehr Avatef Fazeli; Leila Rezaei; Etrat Javadirad; Khosro Iranfar; Abbas Khosravi; Javad Amini Saman; Pardis Poursabbagh; Mohammad Rasoul Ghadami; Mohammad Mehdi Parandin; Amrollah Dehghani; Touraj Ahmadi Jouybari; Behzad Mahdavian; Nastaran Eivazi; Sohbat Rezaei; Alireza Rezaei; Bashir Emami; Mohadeseh Haqgou; Arezoo Bozorgomid; Babak Sayad
Journal:  Mycoses       Date:  2021-07-31       Impact factor: 4.931

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.